| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BICX | Common Stock, par value $0.001 | Award | $0 | +224K | +247.46% | $0.00 | 315K | Apr 24, 2024 | Direct | F1 |
| transaction | BICX | Common Stock, par value $0.001 | Award | $0 | +500K | +158.83% | $0.00 | 815K | Jul 2, 2024 | Direct | F2, F3 |
| transaction | BICX | Common Stock, par value $0.001 | Award | $0 | +15.6K | +1.92% | $0.00 | 830K | Sep 30, 2024 | Direct | F4 |
| transaction | BICX | Common Stock, par value $0.001 | Award | $0 | +13.2K | +1.58% | $0.00 | 844K | Dec 31, 2024 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | These shares were issued to Ms. Felix pursuant to an Exchange Agreement (the "April 2024 Exchange Agreement") by and between BioCorRx Inc. (the "Company") and Ms. Felix dated April 24, 2024. Pursuant to the April 2024 Exchange Agreement, Ms. Felix agreed to the exchange of directors fees in the amount of $265,000 for 224,196 shares of the Company's common stock, par value $0.001 per share (the "Common Stock") at a price of $1.18 per share based on the underlying value of the Common Stock at the date of issuance. |
| F2 | These shares were issued to Ms. Felix pursuant to a Stock Grant Award Agreement (the "Award Agreement") by and between the Company and Ms. Felix, dated July 2, 2024. Pursuant to the Award Agreement, in recognition of Ms. Felix's services to the Company, and for assuming additional responsibilities, the Company issued 500,000 shares of Common Stock to Ms. Felix, representing an amount equal to $235,000, or $0.32 per share based on the closing price of the Common Stock on the date of issuance. These shares are subject to lock-up obligations for a period of 180 days following the date on which the Company's securities become listed for trading on a national securities exchange. |
| F3 | These shares are subject to lock-up obligations for a period of 180 days following the effective date of a registration statement of the Company filed under the Securities Act of 1933, as amended, pursuant to which the Company's securities become listed for trading on a national securities exchange or such longer period to facilitate compliance with FINRA Rule 2241 or any successor or similar rule or regulation. |
| F4 | These shares were issued to Ms. Felix pursuant to a Director Agreement (the "Director Agreement"), dated March 1, 2019, by and between the Company and Ms. Felix. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.32. |
| F5 | These shares were issued to Ms. Felix pursuant to the Director Agreement. As compensation for her services, Ms. Felix shall be issued, upon the last day of each fiscal quarter, provided Ms. Felix is a member of the Board as of such date, the number of shares of Common Stock equivalent to $5,000 as determined based on the average closing price on the three trading days immediately preceding the last day of such quarter. The average closing price on the three trading days immediately preceding the date of this transaction was $0.38. |